| Merck KGaA | 103.60 / -0.31% |
| Date/Time | 10/14 / 10:01 |
| Chg. / Chg.(%) | -0.33 / -0.31% |
| Bid | 103.50 / 100 |
| Ask | 103.60 / 200 |
| Open | 103.35 |
| Previous Close | 103.93 |
| High | 103.80 |
| Low | 103.30 |
| Volume [EUR] | 368,800.85 |
| Volume [Units] | 3,564 |
| Price fixings | 83 |
| ISIN | DE0006599905 |
| Security | MRK/D |
| Exchange | Cboe Europe BXE |
| Type | Stock |
Other Exchanges
| Exchange | Last | Volume | |
|---|---|---|---|
| Xetra | 103.50 |  |
30,235 |
| Turquoise | 103.63 | |
6,161 |
| Cboe Europe .. | 103.60 | |
3,788 |
| Cboe Europe .. | 103.60 | |
3,564 |
| Frankfurt | 103.6500 | |
1,360 |
| Hannover | 103.60 | |
1,300 |
| TradeGate | 103.700 | |
928 |
| London Inter.. | 103.70 | |
644 |
| Stuttgart | 103.650 | |
185 |
| Vienna Globa.. | 103.35 | |
0 |
| Hamburg | 103.30 | |
0 |
| Düsseldorf | 103.65 | |
0 |
| München | 103.70 | |
0 |
| Berlin | 103.30 | |
0 |
| Lang & Schwa.. | 103.450 | |
|
| gettex | 103.600 | |
|
| Nasdaq Other.. | 115.2500 |  |
75 |
| SIX Swiss Ex.. | 102.20 | ||
| SIX Swiss Ex.. | 97.00 | ||
| Borsa Italia.. | 103.35 | 50 | |
| EUREX | Options | ||
News
- Vaccinex Presents Updated Interim Data from a Phase 1b/2 Study of Pepinemab (VX15/2503) in Combination with Avelumab (BAVENCIO®) in Non-Small Cell Lung Cancer in Podium and Poster Presentations at the Fifth International Cancer lmmunotherapy Conference in Paris, France
09/27/2019 / 12:05 - GlobeNewswire - Merck Grant to Support Smithsonian Future Exhibition on History of American Medicine
09/03/2019 / 16:08 - GlobeNewswire - Vaccinex Reports Second Quarter 2019 Financial Results and Provides Corporate Update
08/14/2019 / 14:30 - GlobeNewswire - Vaccinex Announces Full Enrollment Achieved in Ongoing CLASSICAL-Lung Phase 1b/2 Trial of Pepinemab in Combination with BAVENCIO® (avelumab) in Advanced Non-Small Cell Lung Cancer
08/13/2019 / 14:05 - GlobeNewswire - Vaccinex Announces $13.8 Million Private Placement
07/31/2019 / 13:30 - GlobeNewswire
Real-time